Progestins and endometrial cancer

Gynecological Endocrinology

Volumn 15, Issue SUPPL. 6, 2001, Pages 29-36

  Schindler, A E ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Endometrial cancer; Progestins

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; GESTAGEN; TAMOXIFEN;

ADULT; AGED; ENDOMETRIUM TUMOR; FEMALE; HUMAN; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PREMENOPAUSE; REVIEW; RISK FACTOR; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; ENDOMETRIAL NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREMENOPAUSE; PROGESTINS; RISK FACTORS; TAMOXIFEN;

EID: 0142191056     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/gye.15.s6.29.36     Document Type: Article

References (52)

1. American Cancer Society. Cancer statistic 2000. Cancer 2000;50:12
2. König M, Fersis N, Franz H, et al. Endoskopisches Sentinel-Node (ESN)-Verfahren zum laparoskopisch assistierten Staging des Endometriumkarzinoms. Geburtsh Frauenheilk 2000;4:187-90
3. Randall T, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997;90:434-40
4. Saeguse M, Okayasu I. Progesterone therapy for endometrial carcinoma reduces cell proliferation but does not alter apoptosis. Am Cancer Soc 1998; 83:11-121
5. Martin-Hirsch PL, Lilford RJ, Jarvis GJ. Adjuvant progestagen therapy for the treatment of endometrial cancer: review and meta-analyses of published randomized controlled trials. Eur J Obstet Gynecol Reprod Biol 1996;65:201-7
6. Sulak PJ. Endometrial cancer and hormone replacement therapy. Endocrinol Metab Clin North Am. 1997;26: 399-412
7. Parazzini F, La Vecchia C, Bocciolone L, et al. The epidemiology of endometrial cancer. Gynecol Oncol 1991;41:1-16
8. Niwa K, Morishita S, Murase T, et al. Inhibitory effects of medroxyprogesterone acetate on mouse endometrial carcinogenesis. Jpn J Cancer Res 1995; 86:724-9
9. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. Int J Cancer 1991;49:186-90
10. Rose PG. Endometrial carcinoma. N Engl J Med 1996;335:640-9
11. Leo L, Arduino S, Febo G, et al. Endometrial carcinoma in women 45 years of age or younger. Eur J Gynaecol Oncol 1996;XVII:403-5
12. Bokhman JV, Chepick OF, Volkova AT, et al. Adjuvant hormone therapy of primary endometrial carcinoma with oxyprogesterone caproate. Gynecol Oncol 1981;11:371-8
13. Haylock BJ, Murrell DS, Boune H, et al. Stage I endometrial carcinoma: the role of neoadjuvant progesterone therapy. Clin Oncol 1993;5:102-6
14. Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 1984;64:417-20
15. Kempson RL, Pokorny GE. Adeno carcinoma of the endometrium in women aged forty and younger. Cancer 1968;21:650-62
16. Yamazawa K, Seki K, Matsui H, et al. Prognostic factors in young women with endometrial carcinoma: a report of 20 cases and review of literature. Int J Gynecol Cancer 2000;10:212-22
17. Bokhman JV, Chepick OF, Volkova ATZ, et al. Gynecol Oncol 1985;20:139-55
18. Farhi DC, Nosanchuk J, Silverberg SG. Endometrial adenocarcinoma in women under 25 years of age. Obstet Gynecol 1986;68:741-5
19. Kim YB, Holschneider CH, Ghosh K, et al. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Cancer 1997; 79:320-7
20. Lee KR, Scully RE. Complex endometrial hyperplasia and carcinoma in adolescents and young women 15 to 20 years of age. Int J Gynecol Pathol 1989;8:201-13
21. Sardi J, Anche zar Henry JP, Paniceres G, et al. Primary hormonal treatment for early endometrial carcinoma. Eur J Gynaecol Oncol 1998;XIX:565-8
22. Schammel DP, Mittal KR, Kaplan K, et al. Endometrial adenocarcinoma associated with intrauterine pregnancy. Int J Gynecol Pathol 1998;17:327-35
23. Eddy WA. Endometrial carcinoma in Stein-Leventhal syndrome treated with hydroxyprogesterone caproate. Am J Obstet Gynecol 1978; 131:581-5
24. Thornton JG, Brown LA, Wells M, et al. Primary treatment of endometrial cancer with progestagen alone. Lancet 1985;2:207-8
25. Zuckermann B, Lavie O, Neuman M, et al. Endometrial carcinoma stage I - grade II. Conservative treatment followed by a healthy twin pregnancy. Int J Gynecol Cancer 1998;8:172-4
26. Kimmig R, Strowitzki T, Müller-Höcker J, et al. Conservative treatment of endometrial cancer permitting subsequent triplet pregnancy. Gynecol Oncol 1995;58:255-7
27. Niwa K, Yokoyama Y, Tanaka T, et al. Successful pregnancy in a patient with endometrial carcinoma treated with medroxyprogesterone acetate. Arch Gynecol Obstet 1994;255:91-4
28. Zanetta G, Gabriele A, Losa G, et al. Conservative management of endometrial carcinoma with prolonged preservation of the uterus in a young patient. Int J Gynecol Cancer 1997;7:332-4
29. Paulson RJ, Sauer MV, Lobo RA. Pregnancy after in vitro fertilization in a patient with stage I endometrial carcinoma treated with progestins. Fertil Steril 1990;54:735-6
30. Mitsushita J, Toki T, Kato K, et al. Endometrial carcinoma remaining after term pregnancy following conservative treatment with medroxyprogesterone acetate. Gynecol Oncol 2000;79:129-32
31. O'Neill RT. Pregnancy following hormonal therapy for adenocarcinoma of the endometrium. Am J Obstet 1970;108:318-21
32. Vinker S, Shani A, Open M, et al. Conservative treatment of adenocarcinoma of the endometrium in young patients. Is it appropriate? Eur J Obstet Gynecol Reprod Biol 1999;83:63-5
33. Lai C-H, Hsueh S, Chao A-S, et al. Successful pregnancy after tamoxifen and megestrol acetate therapy for endometrial carcinoma. Br J Obstet Gynaecol 1994;101:547-9
34. von Fournier D, Kubli F, Bauer M, et al. Hochdosierte Gestagen-Langzeittherapie beim Korpuskarzinom, Einfluß auf Überlebenszeit. Geburtsh Frauenheilk 1981;41:266
35. Lahousen M, Pickel H. Adjuvant gestagen therapy in stage I endometrial cancer. Zbl Gynecol 1988; 110:1013-17
36. Urbanski K, Karolevski K, Kojs Z, et al. Adjuvant progestagen therapy in survival patients with endometrial cancer after hysterectomy. Results of one institution in a prospective clinical trial. Eur J Gynecol Oncol 1993;14(Suppl):98-104
37. Quinn MA. Adjuvant medroxyprogesterone acetate in high-risk endometrial cancer. Int J Gynecol Cancer 1998;8:387-891
38. Vergote I, Kjorstad K, Abeler V, et al. A randomized trial of adjuvant progestagen in early endometrial cancer. Cancer 1989;64:1011-16
39. Martin-Hirsch PL, Jarvis G, Kitchener H, et al. Progestagens for endometrial cancer. In The Cochrane Library, Issue 3. Oxford Update Software: 2000
40. Schmidt-Matthiesen H, Wellers H. Zur Gestagentherapie fortgeschrittener Korpuskarzinome. Geburtsh Frauenheilk 1968;23:520-31
41. Egeler V. Gestagenbehandlung bei metastasierednden Korpuskarzinom. Schweiz Med Wschr 1971;101:1906-9
42. Vavra N, Salzer H, Sevelda P, et al. Adjuvante Hormontherapie beim Mammakarzinom: Medroxyprogesteronazetat - versus Tamoxifen-Medroxyprogesteronazetat-Sequenztherapie. Gynäkol Rundsch 1990;30:133-43
43. Reifenstein EC. Hydroxyprogesterone caproate therapy in advanced endometrial cancer. Cancer 1971;27:485-502
44. Podratz KC, O'Brien PC, Malkasian GD, et al. Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol 1985;66: 106-10
45. Lentz SS, Brady MF, Major FJ, et al. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a gynaecologic oncology group study. J Clin Oncol 1996;14:357-61
46. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynaecologic Oncology Group. J Clin Oncol 1999;17:1736-44
47. Crespo C, González-Matin A, Lastra E, et al. Metastatic endometrial cancer in lung and liver: complete and prolonged response to hormonal therapy with progestins. Gynecol Oncol 1999;72:250-5
48. Cornelison TL, Baker TR, Piver MS, et al. Cisplatin, adriamycin, etoposide, megestrol acetate versus melphalan, 5-fluorouracil, medroxyprogesterone acetate in the treatment of endometrial carcinoma. Gynecol Oncol 1995:59:243-8
49. Bafaloukos D, Aravantinos G, Samonis G, et al. Carboplatin, methotrexate and 5-fluorouracil in combination with medroxyprogesterone acetate (JMF-M) in the treatment of advanced or recurrent endometrial carcinoma: a Hellenic Cooperative Oncology Group study. Oncology 1999;56: 198-201
50. Pinelli DM, Fiorica JV, Roberts WS, et al. Chemotherapy plus sequential hormonal therapy for advanced and recurrent endometrial carcinoma. A phase II study. Gynecol Oncol 1996;60:462-7
51. Kung F-T, Chen W-J, Chou H-H, Ko S-F, Chang S-Y. Conservative management of early endometrial adenocarcinoma with repeat curettage and hormone therapy under assistance of hysteroscopy and laparoscopy. Hum Reprod 1997;12:1649-53
52. Ogawa S, Koike T, Shibahara H, et al. Assisted reproductive technologies in conjunction with conservatively treated endometrial adenocarcinoma. Gynecol Obstet Invest 2001;51:214-16